Clinical effects and toxicity of interleukin‐2 in patients with cancer

Keyphrases

• Weight Gain 100%
• Clinical Toxicity 100%
• Patients with Cancer 100%
• Clinical Effect 100%
• T Cells 66%
• Recombinant 66%
• Jurkat 66%
• Tumor 33%
• AIDS/HIV 33%
• Glycoprotein 33%
• Solid Tumors 33%
• Melanoma 33%
• High Dose 33%
• Cumulative Dose 33%
• Lung 33%
• Eosinophilia 33%
• Malignancy 33%
• Immune Response 33%
• Adoptive Transfer 33%
• Clinical Parameters 33%
• Partial Response 33%
• Thrombocytopenia 33%
• Hematotoxicity 33%
• Natural Killer Cells 33%
• Maximum Tolerated Dose 33%
• Mild Anaemia 33%
• Renal Toxicity 33%
• Single Bolus 33%
• Immunological Status 33%
• Malaise 33%
• Hepatic Toxicity 33%
• Murine Tumor Model 33%
• Recombinant Escherichia Coli 33%

Nursing and Health Professions

• Neoplasm 100%
• Acquired Immune Deficiency Syndrome 100%
• Anemia 100%
• Thrombocytopenia 100%
• Drug Megadose 100%
• Metastatic Melanoma 100%
• Adoptive Transfer 100%
• Maximum Permissible Dose 100%
• Glycoprotein 100%
• Tumor Model 100%
• Solid Malignant Neoplasm 100%
• Malaise 100%
• Eosinophilia 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Recombinant 100%
• Neoplasm 50%
• Acquired Immune Deficiency Syndrome 50%
• Anemia 50%
• Solid Malignant Neoplasm 50%
• Eosinophilia 50%
• Escherichia coli 50%
• Metastatic Melanoma 50%
• Tumor Model 50%
• Glycoprotein 50%
• Thrombocytopenia 50%
• Nephrotoxicity 50%
• Murine 50%
• Malaise 50%
• Hepatic Toxicity 50%